Afrezza Kit
Product Images NDC 47918-902

Product Visual Gallery

This gallery contains 47 technical images submitted to the FDA as part of the official labeling for Afrezza (NDC 47918-902). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mannkind Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Afr01 0008 01)

A line graph comparing the change from baseline in forced expiratory volume (FEV1, in liters) over time between AFREZZA and a comparator. The x-axis shows visits from baseline through month 24, with data points at months 3, 6, 9, 12, 18, and 24. The y-axis measures change in FEV1, ranging from -0.3 to 0.1 liters. AFREZZA shows a greater decrease in FEV1 than the comparator at each time point.*

FDA Label Image

Primary Amino Acid Sequence (Afr01 0008 02)

Chemical structure diagram illustrating the amino acid sequence and disulfide bridges of human insulin, the active ingredient in AFREZZA inhalation powder. The structure depicts the two peptide chains linked by disulfide bonds.*

FDA Label Image

Figure 2 (Fig 3 Ab)

Two graphs labeled A and B show pharmacokinetic data for AFREZZA inhalation powder at doses of 4, 12, and 48 units. Graph A plots glucose infusion rate (GIR, mg/kg/min) over 360 minutes, illustrating dose-dependent increases and decreases in GIR. Graph B depicts insulin concentration (µU/mL) over 360 minutes, showing peak insulin levels and decline over time for the three doses of AFREZZA.*

FDA Label Image

A (Fig A)

An instructional diagram showing the parts of an Afrezza inhaler, including the top and bottom of the device, removable purple mouthpiece cover, white mouthpiece, cartridge, white cartridge cup, and purple base. The diagram illustrates the assembly of the cartridge into the inhaler.*

FDA Label Image

B (Fig B)

Illustration showing Afrezza insulin human cartridges with meter markings by color: 4 unit in blue, 8 unit in green, and 12 unit in yellow. Each cartridge features a white cup, with the diagram labeling the cartridge and white cup components.*

FDA Label Image

C (Fig C)

Storage and usage instruction chart for AFREZZA insulin human inhalation powder. It details storage durations for unopened foil packages, blister cards/strips, opened blister strips, unused sealed inhalers, and opened in-use inhalers at refrigerator and room temperature conditions, with specific timelines and warnings, such as not storing opened blister strips in the refrigerator.*

FDA Label Image

Figured (Fig D)

An illustrated dosing chart for AFREZZA insulin inhalation powder showing combinations of 4 unit (blue), 8 unit (green), and 12 unit (yellow) cartridges to achieve total doses of 4, 8, 12, 16, 20, and 24 units. It visually represents which cartridge colors and quantities correspond to each dose, with a note that other combinations can be used.*

FDA Label Image

Fige (Fig E)

Packaging label for AFREZZA inhalation powder by Mannkind Corporation. It shows the product name, active ingredient insulin human (rDNA origin), dosage form as powder for respiratory inhalation, and mentions dosage units per cartridge with instructions to inhale once and discard the cartridge. The label is primarily gray and white with black text and a red border at the bottom.*

FDA Label Image

2.2 (Step 2.2)

This text panel provides important storage instructions for AFREZZA insulin human powder metered inhalation cartridges, emphasizing the return of unopened blister cards or strips to the refrigerator and cautioning against use if stored beyond recommended periods as detailed in the Storage Information section.*

FDA Label Image

F (Fig F)

An instructional illustration for the AFREZZA inhalation powder showing hands removing a single blister unit from a multi-strip carton. The label on each blister displays the proprietary name AFREZZA, the generic name insulin human inhalation powder, and dosage information. The image demonstrates how to separate and take out individual blister units for use.*

FDA Label Image

2.3 (Step 2.3)

A safety warning text panel from AFREZZA (insulin human) inhalation powder instructing not to use cartridges if the expiration date has passed.*

FDA Label Image

G (Fig G)

An instructional figure labeled 'Figure G' showing where to check the expiration date on the AFREZZA insulin human inhalation powder cartridge. It highlights the expiration date format as YYYY-MM-DD and includes a depiction of the cartridge label showing the expiration date location and dosage strength markings.*

FDA Label Image

H (Fig H)

An instructional illustration showing hands removing a single dose of AFREZZA inhalation powder cartridge from a blister pack to insert into an inhaler device. The figure demonstrates how to properly handle the cartridge for administration.*

FDA Label Image

3.2 (Step 3.2)

A text warning panel instructing not to use cold cartridge(s) or inhaler until they have been allowed to come to room temperature. The text is displayed in a box with a red border.*

FDA Label Image

I (Fig I)

Illustration showing an AFREZZA inhaler and two cartridge components beside a stopwatch displaying 10 minutes. Text instructs to allow the device to sit at room temperature for 10 minutes before use.*

FDA Label Image

3.3 (Step 3.3)

A text panel providing storage and usage instructions for AFREZZA cartridges. It advises against using cartridges incorrect for the dose, instructs storing opened blister strips at room temperature, warns not to refrigerate opened strips, and refers to the Storage Information section for more details.*

FDA Label Image

J (Fig J)

An instructional diagram showing how to check that cartridges are correct before use. It includes two detailed cartridge illustrations and a visual cue to verify by looking closely, with a large green checkmark indicating correctness. The figure is labeled as 'Figure J'.*

FDA Label Image

K (Fig K)

Illustration showing a hand holding a purple and white device, demonstrating the action of pulling the purple part upward with an arrow indicating the motion. The image likely depicts part of the preparation or use process for AFREZZA, insulin human powder for inhalation.*

FDA Label Image

L (Fig L)

Instructional illustration showing how to insert a cartridge into the AFREZZA inhaler device. A hand is placing the cartridge with the pointed end aligned in the designated slot of the purple inhaler base, demonstrating proper insertion for use.*

FDA Label Image

Warni (Warning)

A warning panel for AFREZZA inhaler powder, instructing to keep the inhaler level when loading the cartridge to avoid spilling powder. It provides steps to follow if the powder spills, including discarding the cartridge, washing hands if contacted, and reloading with a new cartridge as directed.*

FDA Label Image

Figm (Fig M)

An instructional illustration titled 'Figure M' showing the AFREZZA inhaler device positioned horizontally on a flat surface. Above the image is a graphic of the inhaler's dose indicator with a message to 'Keep the inhaler level,' emphasizing proper device orientation for use.*

FDA Label Image

N (Fig N)

An instructional illustration labeled Figure N showing a hand opening a cap or cover on a purple device, with an arrow indicating the downward motion to open or access the device, related to AFREZZA inhalation powder administration.*

FDA Label Image

5 (Step 5)

A highlighted note instructing to read steps 5 and 6 completely before attempting to inhale AFREZZA, emphasizing the importance of following instructions for this inhalation drug product.*

FDA Label Image

5.1 (Step 5.1)

An instructional text panel emphasizing the importance of keeping the AFREZZA inhaler level until it is placed in the mouth to prevent spilling the powder. The text highlights proper handling to ensure correct inhalation of AFREZZA insulin human powder.*

FDA Label Image

Figo (Fig O)

Instructional illustration showing the removal of a protective cap from the mouthpiece of a device, likely demonstrating a preparation step for use. The image depicts two hands: one holding the device and the other pulling off the mouthpiece cap, as indicated by a black arrow.*

FDA Label Image

5.3 (Step 5.3)

A text panel displaying an instruction to keep the AFREZZA inhaler level until the mouthpiece is in the mouth to prevent powder spillage. The text emphasizes handling guidance for the AFREZZA powder inhaler device.*

FDA Label Image

P (Fig P)

An instructional illustration showing a person holding an Afrezza inhaler. The image emphasizes the correct inhaler positioning with the instructions to "Sit Upright with Head level" and "Keep Inhaler Level." The inhaler is held close to the mouth, demonstrating proper use posture for respiratory administration.*

FDA Label Image

6.1 (Step 6.1)

A text warning panel displaying the instruction 'Do not blow into the inhaler.' The text emphasizes proper usage caution for the inhalation device associated with AFREZZA insulin powder.*

FDA Label Image

Q (Fig Q)

An instructional illustration showing a person exhaling with the text 'Breathe Out'. The person holds a small inhalation device, likely for AFREZZA insulin, near the mouth, demonstrating proper inhalation preparation technique.*

FDA Label Image

R (Fig R)

An instructional illustration demonstrating how to use the AFREZZA inhalation device. It shows a person placing the device in their mouth and tilting it, with an arrow indicating the correct placement and orientation. This guides proper administration of the powdered insulin human dosage.*

FDA Label Image

S (Fig S)

An instructional diagram showing a person inhaling a dose from an AFREZZA inhaler device, labeled "Breathe In" with blue swirls indicating the inhalation flow toward the mouth.*

FDA Label Image

T (Fig T)

Illustration labeled 'Figure T' depicting a side profile of a person's lower face and neck with lips slightly parted, alongside the instruction text 'Hold Breath'. This image is likely part of inhalation usage instructions for AFREZZA, an insulin human powder for respiratory inhalation by Mannkind Corporation.*

FDA Label Image

U (Fig U)

An instructional illustration showing a close-up of two hands assembling or attaching a purple and gray component, likely part of the AFREZZA insulin inhalation device. A black arrow indicates the direction to pull or connect the piece, demonstrating device preparation or use.*

FDA Label Image

V (Fig V)

An instructional illustration showing hands operating a device, likely related to AFREZZA inhalation powder. The image depicts one hand lifting or opening a purple and white device with an upward curved arrow indicating the motion.*

FDA Label Image

7.3 (Step 7.3)

This text panel provides a safety instruction advising users to wash their hands immediately if any medicine from the cartridge spills on them. The instruction is presented in a bold and clear manner inside a bordered box for emphasis.*

FDA Label Image

W (Fig W)

An instructional illustration showing a hand placing a small rectangular component into a purple and white inhaler device, indicating the proper insertion direction with an upward arrow. The image appears to guide assembly or loading of the AFREZZA inhalation device for insulin human powder delivery.*

FDA Label Image

X (Fig X)

An instructional illustration showing a hand disposing of a small medical device or component into a trash container labeled 'TRASH.' This figure indicates proper disposal of the item, likely related to the AFREZZA inhalation powder delivery system.*

FDA Label Image

Y (Fig Y)

An illustration showing usage instructions for AFREZZA inhalation powder device. The left panel depicts a hand inserting a cartridge into the purple inhaler device. The right panel shows a person holding the inhaler to their mouth and inhaling, with airflow indicated by blue curved lines.*

FDA Label Image

Z (Fig Z)

This warning panel instructs users not to reuse AFREZZA cartridges, emphasizing single use only. It cautions against mixing new and used cartridges, noting that the white cup moves to the middle when a cartridge is used. Figure Z illustrates the appearance of new versus used cartridges, with images showing top and side views for comparison.*

FDA Label Image

Aa (Fig Aa)

An illustration of a calendar page showing days 1 through 15, with days 1-14 crossed out in red and day 15 circled in red. The calendar header is blue with the word 'CALENDAR' in white. The bottom right corner of the page is slightly curled up.*

FDA Label Image

Principal Display Panel 90 − 4 Unit Cartridges And 2 Inhalers (Afr01 0008 33)

Packaging label for AFREZZA (insulin human) Inhalation Powder by Mannkind Corporation. The label indicates the product is powder for metered respiratory (inhalation) use, containing 90 single-use cartridges with 4 units per cartridge, along with 2 inhalers. The carton features usage instructions, dose cartridge suggestions, and a replace-your-inhaler calendar.*

FDA Label Image

Principal Display Panel 90 – 8 Unit Cartridges And 2 Inhalers (Afr01 0008 34)

Packaging label for AFREZZA inhalation powder by Mannkind Corporation. The box contains 90 single-use cartridges, each providing 8 units of insulin human powder for respiratory inhalation. The label indicates the dosage form as metered powder, designed for oral inhalation only. The packaging also includes instructions for cartridge use and replacement.*

FDA Label Image

Principal Display Panel 90 – 12 Unit Cartridges And 2 Inhalers (Afr01 0008 35)

Packaging label for AFREZZA inhalation powder, an insulin human metered powder for respiratory (inhalation) use. The label shows a strength of 12 units per cartridge and contains 90 single-use cartridges plus 2 inhalers. The labeler is Mannkind Corporation. Instructions for use, dose suggestions, and replacement calendar for the inhaler are included on the label.*

FDA Label Image

Principal Display Panel 180 Cartridges; 60 – 4 Unit Cartridges, 60 – 8 Unit Cartridges And 60 – 12 Unit Cartridges And 2 Inhalers (titration Pack) (Afr01 0008 36)

Packaging label for Afrezza (insulin human) inhalation powder by Mannkind Corporation. The label displays a titration pack containing 180 single-use cartridges in strengths of 4, 8, and 12 units per cartridge along with 2 inhalers. The label includes color-coded cartridge images, dosage and usage instructions, and a calendar guide for inhaler replacement every 15 days.*

FDA Label Image

Principal Display Panel 180 Cartridges; 90 – 4 Unit Cartridges And 90 – 8 Unit Cartridges And 2 Inhalers (titration Pack) (Afr01 0008 37)

Packaging label for Afrezza inhalation powder containing insulin human in metered powder form for respiratory (inhalation) use. The carton is labeled as a titration pack with 180 single-use cartridges in strengths of 4 units and 8 units per cartridge, including 2 inhalers. The labeler is Mannkind Corporation. The packaging includes instructions for cartridge and inhaler use, replacement guidance, and dosage suggestions.*

FDA Label Image

Principal Display Panel 180 Cartridges; 90 – 8 Unit Cartridges And 90 – 12 Unit Cartridges And 2 Inhalers (Afr01 0008 38)

Packaging label for AFREZZA (insulin human) inhalation powder by Mannkind Corporation. The label shows a meter dosed powder form for respiratory inhalation with available strengths of 4, 8, and 12 units per cartridge. The carton contains 180 single-use cartridges and 2 inhalers, with dosage guidance and inhaler usage instructions illustrated. The label features brand and generic names, dosage form, quantity, and manufacturer details.*

FDA Label Image

Afr01-0008-39 (Afr01 0008 39)

AFREZZA (insulin human) Inhalation Powder carton for a sample pack containing 30 single-use cartridges with strengths of 4 units and 8 units per cartridge. The packaging includes a purple and white design with product name and usage instructions. It also shows a dosing conversion table and images of cartridges and an inhaler device. Labeler is Mannkind Corporation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.